Last updated: 04.03.2015

medipost_logoMEDIPOST has dedicated its focus on biotechnology from its foundation in year 2000 until today, in spite of numerous adversities, rises and falls within the stem cell area.

As a result, MEDIPOST has become a frontrunner in the field of the biopharmaceuticals not only in Korea but also in the world. MEDIPOST with its state-of-the-art platform technology has led to the development and approval of the world’s first allogeneic stem cell therapy product – CARTISTEM®.

MEDIPOST continues its endeavors on clinical development and commercialization of stem cell therapeutics to improve quality of lives of many patients with intractable diseases not only in Korea, but also around the globe.

Contact Details:

21, Daewangpangyo-ro 644 (Sampyeong-dong), Bundang-gu, Seongnam-si, Gyeonggi-do, Korea

MEDIPOST Co., Ltd. CEO Yang, Yoon Sun

Business Registration No.: 211-86-61218

TEL : 82-2-3465-6650 / FAX : 82-2-3465-6688



We use cookies to ensure that we give you the best experience on our site. For more info click here